For example, bortezomib, a selective inhibitor of the β5 subunit of the proteasome (PSMB5), has exhibited significant success in the treatment of patients with multiple myeloma and diffuse large B-cell lymphoma [135], probably because of the high secretory activity of these cells. Here, PSMB5 is linked to plasma cell myeloma.